IP Library › Granted Patent US 12,202,910
Granted Patent B2
US 12,202,910 · App. 17/849,467 · Granted Jan 21, 2025

Antibodies specific for FLT3 and their uses

Inventors: Danielle Elizabeth Dettling (San Francisco, CA); Yik Andy Yeung (South San Francisco, CA); Kristian Todd Poulsen (San Francisco, CA); Veena Krishnamoorthy (Burlingame, CA); Cesar Adolfo Sommer (San Mateo, CA)
Assignee: PFIZER INC.
C07K16/461A61P35/00A61P35/02C07K16/2809C07K16/2863A61K2039/505C07K2317/21C07K2317/31C07K2317/33C07K2317/52C07K2317/62C07K2317/71C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,910
App. No.
17/849,467
Granted
Jan 21, 2025
Kind
B2
Abstract

The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).

Claims (92)

1. A nucleic acid encoding an antibody, which specifically binds to Fms-like tyrosine kinase 3 (FLT3), wherein the antibody comprises:

(a) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 37, 38 or 39; a VH CDR2 comprising the sequence shown in SEQ ID NO: 40 or 41; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 42; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 144; a VL CDR2 comprising the sequence shown in SEQ ID NO: 145; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 146;

(b) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 43, 44, or 45; a VH CDR2 comprising the sequence shown in SEQ ID NO: 46 or 47; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 48; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 147; a VL CDR2 comprising the sequence shown in SEQ ID NO: 148; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 149;

(c) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 54, 55 or 56; a VH CDR2 comprising the sequence shown in SEQ ID NO: 57 or 58; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 59; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 153; a VL CDR2 comprising the sequence shown in SEQ ID NO: 154; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 155;

(d) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 66, 67 or 68; a VH CDR2 comprising the sequence shown in SEQ ID NO: 69 or 70; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 71; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 159; a VL CDR2 comprising the sequence shown in SEQ ID NO: 160; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 161;

(e) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 72, 73 or 74; a VH CDR2 comprising the sequence shown in SEQ ID NO: 75 or 76; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 77; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 162; a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 164;

(f) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 78, 79 or 80; a VH CDR2 comprising the sequence shown in SEQ ID NO: 81 or 82; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 83; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 165; a VL CDR2 comprising the sequence shown in SEQ ID NO: 166; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 167;

(g) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 96, 97 or 98; a VH CDR2 comprising the sequence shown in SEQ ID NO: 99 or 100; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 101; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 174; a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 176;

(h) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(i) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 114, 115 or 116; a VH CDR2 comprising the sequence shown in SEQ ID NO: 117 or 118; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 119; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 183; a VL CDR2 comprising the sequence shown in SEQ ID NO: 184; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 185;

(j) (o) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 120, 121 or 122; a VH CDR2 comprising the sequence shown in SEQ ID NO: 123 or 124; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 125; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 186; a VL CDR2 comprising the sequence shown in SEQ ID NO: 187; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 188;

(k) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 126, 127 or 128; a VH CDR2 comprising the sequence shown in SEQ ID NO: 129 or 130; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 131; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 189; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 191;

(l) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 132, 133 or 134; a VH CDR2 comprising the sequence shown in SEQ ID NO: 135 or 136; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 137; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 192; a VL CDR2 comprising the sequence shown in SEQ ID NO: 193; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 194;

(m) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 138, 139 or 140; a VH CDR2 comprising the sequence shown in SEQ ID NO: 141 or 142; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 143; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 195; a VL CDR2 comprising the sequence shown in SEQ ID NO: 196; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 197;

(n) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 126, 127 or 128; a VH CDR2 comprising the sequence shown in SEQ ID NO: 129 or 130; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 245; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 189; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 256;

(o) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 247, 127 or 246; a VH CDR2 comprising the sequence shown in SEQ ID NO: 248 or 249; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 250; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 257; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 258;

(p) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 72, 73 or 74; a VH CDR2 comprising the sequence shown in SEQ ID NO: 100 or 251; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 77; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 174; a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 176;

(q) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 49, 44 or 50; a VH CDR2 comprising the sequence shown in SEQ ID NO: 253 or 252; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 254; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 260;

(r) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(s) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(t) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 138, 139 or 140; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 275; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264;

(u) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 261; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 262;

(v) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 263; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264;

(w) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 265; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 267;

(x) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 268; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 269;

(y) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 270; a VL CDR2 comprising the sequence shown in SEQ ID NO: 271; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 272;

(z) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 273; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 274; or

(aa) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 275; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264.

2. A nucleic acid encoding an antibody, which specifically binds to Fms-like tyrosine kinase 3 (FLT3), wherein the antibody comprises:

(a) a VH region comprising the VH sequence shown in SEQ ID NO: 2, and a VL region comprising the VL sequence shown in SEQ ID NO: 1;

(b) a VH region comprising the VH sequence shown in SEQ ID NO: 4, and a VL region comprising the VL sequence shown in SEQ ID NO: 3;

(c) a VH region comprising the VH sequence shown in SEQ ID NO: 8, and a VL region comprising the VL sequence shown in SEQ ID NO: 7;

(d) a VH region comprising the VH sequence shown in SEQ ID NO: 12, and a VL region comprising the VL sequence shown in SEQ ID NO: 11;

(e) a VH region comprising the VH sequence shown in SEQ ID NO: 14, and a VL region comprising the VL sequence shown in SEQ ID NO: 13;

(f) a VH region comprising the VH sequence shown in SEQ ID NO: 16, and a VL region comprising the VL sequence shown in SEQ ID NO: 15;

(g) a VH region comprising the VH sequence shown in SEQ ID NO: 22, and a VL region comprising the VL sequence shown in SEQ ID NO: 21;

(h) a VH region comprising the VH sequence shown in SEQ ID NO: 24, and a VL region comprising the VL sequence shown in SEQ ID NO: 23;

(i) a VH region comprising the VH sequence shown in SEQ ID NO: 28, and a VL region comprising the VL sequence shown in SEQ ID NO: 27;

(j) a VH region comprising the VH sequence shown in SEQ ID NO: 30, and a VL region comprising the VL sequence shown in SEQ ID NO: 29;

(k) a VH region comprising the VH sequence shown in SEQ ID NO: 32, and a VL region comprising the VL sequence shown in SEQ ID NO: 31;

(l) a VH region comprising the VH sequence shown in SEQ ID NO: 34, and a VL region comprising the VL sequence shown in SEQ ID NO: 33;

(m) a VH region comprising the VH sequence shown in SEQ ID NO: 36, and a VL region comprising the VL sequence shown in SEQ ID NO: 35;

(n) a VH region comprising the VH sequence shown in SEQ ID NO: 205, and a VL region comprising the VL sequence shown in SEQ ID NO: 204;

(o) a VH region comprising the VH sequence shown in SEQ ID NO: 207, and a VL region comprising the VL sequence shown in SEQ ID NO: 206;

(p) a VH region comprising the VH sequence shown in SEQ ID NO: 209, and a VL region comprising the VL sequence shown in SEQ ID NO: 208;

(q) a VH region comprising the VH sequence shown in SEQ ID NO: 211, and a VL region comprising the VL sequence shown in SEQ ID NO: 210;

(r) a VH region comprising the VH sequence shown in SEQ ID NO: 213, and a VL region comprising the VL sequence shown in SEQ ID NO: 212;

(s) VH region comprising the VH sequence shown in SEQ ID NO: 215, and a VL region comprising the VL sequence shown in SEQ ID NO: 214;

(t) a VH region comprising the VH sequence shown in SEQ ID NO: 217, and a VL region comprising the VL sequence shown in SEQ ID NO: 216;

(u) a VH region comprising the VH sequence shown in SEQ ID NO: 219, and a VL region comprising the VL sequence shown in SEQ ID NO: 218;

(v) a VH region comprising the VH sequence shown in SEQ ID NO: 221, and a VL region comprising the VL sequence shown in SEQ ID NO: 220;

(w) a VH region comprising the VH sequence shown in SEQ ID NO: 223, and a VL region comprising the VL sequence shown in SEQ ID NO: 222;

(x) a VH region comprising the VH sequence shown in SEQ ID NO: 225, and a VL region comprising the VL sequence shown in SEQ ID NO: 224;

(y) a VH region comprising the VH sequence shown in SEQ ID NO: 227, and a VL region comprising the VL sequence shown in SEQ ID NO: 226;

(z) a VH region comprising the VH sequence shown in SEQ ID NO: 229, and a VL region comprising the VL sequence shown in SEQ ID NO: 228;

(aa) a VH region comprising the VH sequence shown in SEQ ID NO: 231, and a VL region comprising the VL sequence shown in SEQ ID NO: 230; or

(bb) a VH region comprising the VH sequence shown in SEQ ID NO: 233, and a VL region comprising the VL sequence shown in SEQ ID NO: 232.

3. A vector comprising the nucleic acid of claim 1 .

4. A vector comprising the nucleic acid of claim 2 .

5. A cell comprising the vector of claim 3 .

6. A cell comprising the vector of claim 4 .

7. A method of treating a subject in need thereof comprising:

(a) providing the antibody encoded by the nucleic acid of claim 1 ; and

(b) administering said antibody to said subject.

8. A bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen, and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antibody variable domain comprises:

(a) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 37, 38 or 39; a VH CDR2 comprising the sequence shown in SEQ ID NO: 40 or 41; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 42; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 144; a VL CDR2 comprising the sequence shown in SEQ ID NO: 145; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 146;

(b) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 43, 44, or 45; a VH CDR2 comprising the sequence shown in SEQ ID NO: 46 or 47; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 48; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 147; a VL CDR2 comprising the sequence shown in SEQ ID NO: 148; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 149;

(c) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 54, 55 or 56; a VH CDR2 comprising the sequence shown in SEQ ID NO: 57 or 58; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 59; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 153; a VL CDR2 comprising the sequence shown in SEQ ID NO: 154; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 155;

(d) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 66, 67 or 68; a VH CDR2 comprising the sequence shown in SEQ ID NO: 69 or 70; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 71; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 159; a VL CDR2 comprising the sequence shown in SEQ ID NO: 160; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 161;

(e) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 72, 73 or 74; a VH CDR2 comprising the sequence shown in SEQ ID NO: 75 or 76; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 77; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 162; a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 164;

(f) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 78, 79 or 80; a VH CDR2 comprising the sequence shown in SEQ ID NO: 81 or 82; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 83; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 165; a VL CDR2 comprising the sequence shown in SEQ ID NO: 166; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 167;

(g) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 96, 97 or 98; a VH CDR2 comprising the sequence shown in SEQ ID NO: 99 or 100; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 101; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 174; a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 176;

(h) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(i) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 114, 115 or 116; a VH CDR2 comprising the sequence shown in SEQ ID NO: 117 or 118; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 119; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 183; a VL CDR2 comprising the sequence shown in SEQ ID NO: 184; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 185;

(j) (o) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 120, 121 or 122; a VH CDR2 comprising the sequence shown in SEQ ID NO: 123 or 124; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 125; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 186; a VL CDR2 comprising the sequence shown in SEQ ID NO: 187; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 188;

(k) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 126, 127 or 128; a VH CDR2 comprising the sequence shown in SEQ ID NO: 129 or 130; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 131; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 189; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 191;

(l) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 132, 133 or 134; a VH CDR2 comprising the sequence shown in SEQ ID NO: 135 or 136; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 137; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 192; a VL CDR2 comprising the sequence shown in SEQ ID NO: 193; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 194;

(m) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 138, 139 or 140; a VH CDR2 comprising the sequence shown in SEQ ID NO: 141 or 142; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 143; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 195; a VL CDR2 comprising the sequence shown in SEQ ID NO: 196; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 197;

(n) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 126, 127 or 128; a VH CDR2 comprising the sequence shown in SEQ ID NO: 129 or 130; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 245; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 189; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 256;

(o) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 247, 127 or 246; a VH CDR2 comprising the sequence shown in SEQ ID NO: 248 or 249; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 250; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 257; a VL CDR2 comprising the sequence shown in SEQ ID NO: 190; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 258;

(p) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 72, 73 or 74; a VH CDR2 comprising the sequence shown in SEQ ID NO: 100 or 251; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 77; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 174; a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 176;

(q) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 49, 44 or 50; a VH CDR2 comprising the sequence shown in SEQ ID NO: 253 or 252; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 254; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 260;

(r) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(s) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 177; a VL CDR2 comprising the sequence shown in SEQ ID NO: 178; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 179;

(t) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 138, 139 or 140; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 275; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264;

(u) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 261; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 262;

(v) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 263; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264;

(w) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 265; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 267;

(x) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 268; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 269;

(y) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 270; a VL CDR2 comprising the sequence shown in SEQ ID NO: 271; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 272;

(z) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 273; a VL CDR2 comprising the sequence shown in SEQ ID NO: 266; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 274; or

(aa) a heavy chain variable (VH) region comprising: a VH CDR1 comprising the sequence shown in SEQ ID NO: 102, 103 or 104; a VH CDR2 comprising the sequence shown in SEQ ID NO: 255 or 106; and a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a light chain variable (VL) region comprising a VL CDR1 comprising the sequence shown in SEQ ID NO: 275; a VL CDR2 comprising the sequence shown in SEQ ID NO: 259; and a VL CDR3 comprising the sequence shown in SEQ ID NO: 264.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: RINAT NEUROSCIENCE CORP.
To: PFIZER INC.
Reel/Frame 061422/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: DETTLING, DANIELLE ELIZABETH; YEUNG, YIK ANDY; POULSEN, KRISTIAN TODD
To: RINAT NEUROSCIENCE CORP.
Reel/Frame 061422/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: DETTLING, DANIELLE ELIZABETH; YEUNG, YIK ANDY; POULSEN, KRISTIAN TODD; KRISHNAMOORTHY, VEENA; SOMMER, CESAR ADOLFO
To: PFIZER INC.
Reel/Frame 061422/0715 →
Continuity (4)
Division 15993874 · May 31, 2018
Provisional Application 62660908 · Apr 20, 2018
Provisional Application 62514574 · Jun 2, 2017
Related Publication 20230059489A1 · Feb 23, 2023
References Cited (97)
US 5635388A · Bennett · 1997 [cited by applicant]
US 7125659B1 · Kiyoi · 2006 [cited by applicant]
US 8921528B2 · Holt et al. · 2014 [cited by applicant]
US 9023996B2 · Grosse-Hovest · 2015 [cited by examiner]
US 11421040B2 · Dettling et al. · 2022 [cited by applicant]
US 20060128788A1 · Baumann · 2006 [cited by applicant]
US 20060281755A1 · Baumann · 2006 [cited by applicant]
US 20060281771A1 · Baumann · 2006 [cited by applicant]
US 20070149572A1 · Ballentine · 2007 [cited by applicant]
US 20070225306A1 · Choi · 2007 [cited by applicant]
US 20080213251A1 · Sexton · 2008 [cited by applicant]
US 20090054358A1 · Small · 2009 [cited by applicant]
US 20090169562A1 · Throsby · 2009 [cited by applicant]
US 20090297529A1 · Li et al. · 2009 [cited by applicant]
US 20090311183A1 · Devy · 2009 [cited by applicant]
US 20100278834A1 · Lanzavecchia · 2010 [cited by applicant]
US 20110142851A1 · Misher · 2011 [cited by applicant]
US 20110152173A1 · Lofquist · 2011 [cited by applicant]
US 20110200611A1 · Sexton · 2011 [cited by applicant]
US 20110268739A1 · Throsby · 2011 [cited by applicant]
US 20110275094A1 · Gunawardane · 2011 [cited by applicant]
US 20120328612A1 · Grosse-Hovest · 2012 [cited by applicant]
US 20130052205A1 · Valmier · 2013 [cited by applicant]
US 20130156764A1 · Levis · 2013 [cited by applicant]
US 20130171148A1 · De Goeij · 2013 [cited by applicant]
US 20130177572A1 · Chen · 2013 [cited by applicant]
US 20130288373A1 · Verstraete · 2013 [cited by applicant]
US 20140170149A1 · Neijssen · 2014 [cited by applicant]
US 20140245490A1 · Crawford · 2014 [cited by applicant]
US 20150104479A1 · Romano et al. · 2015 [cited by applicant]
US 20150110819A1 · Sette · 2015 [cited by applicant]
US 20150307615A1 · Panousis · 2015 [cited by applicant]
US 20160244750A1 · Vasquez · 2016 [cited by applicant]
US 20160272716A1 · Lowe · 2016 [cited by applicant]
US 20160297884A1 · Kuo et al. · 2016 [cited by applicant]
US 20160297885A1 · Kuo et al. · 2016 [cited by applicant]
US 20160297888A1 · Zhou et al. · 2016 [cited by applicant]
US 20160311903A1 · West · 2016 [cited by applicant]
US 20160362472A1 · Bitter · 2016 [cited by applicant]
US 20170037149A1 · Raum · 2017 [cited by applicant]
US 20170088620A1 · Nioi · 2017 [cited by applicant]
US 20170129961A1 · Raum · 2017 [cited by applicant]
US 20180346601A1 · Dettling et al. · 2018 [cited by applicant]
AU 2018275359B2 · 2021 [cited by applicant]
CN 104288765A · 2015 [cited by applicant]
EA 12622B1 · 2009 [cited by applicant]
EP 3029067A1 · 2016 [cited by applicant]
JP A2011521647 · 2011 [cited by applicant]
JP 2017513478A · 2017 [cited by applicant]
WO WO2003074059A2 · 2003 [cited by applicant]
WO WO2005110392A1 · 2005 [cited by applicant]
WO WO2009155015A1 · 2009 [cited by applicant]
WO WO2011076922A1 · 2011 [cited by applicant]
WO WO2012094115A1 · 2012 [cited by applicant]
WO WO2013040142A2 · 2013 [cited by applicant]
WO WO2013092001A1 · 2013 [cited by applicant]
WO WO2013174832A1 · 2013 [cited by applicant]
WO 2014011988A2 · 2014 [cited by applicant]
WO 2016012021A1 · 2016 [cited by applicant]
WO WO2016016859A1 · 2016 [cited by applicant]
WO WO2016145099A1 · 2016 [cited by applicant]
WO WO2016164637A1 · 2016 [cited by applicant]
WO WO2017021362A1 · 2017 [cited by applicant]
WO WO2017053889A2 · 2017 [cited by applicant]
WO 2018220584A1 · 2018 [cited by applicant]
WO WO2018222935A1 · 2018 [cited by applicant]
Abu-Duhier et al., “FLT3 Internal Tandem Duplication Mutations in Adult Acute Myeloid Leukemia Define a High-Risk Group,” Br J Haematol. 111 (1):190-195 (Oct. 2000). [cited by applicant]
Almagro & Fransson, “Humanization of antibodies,” Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008). [cited by applicant]
Birg et al., “Expression of the FMS/KIT-Like Gene FL T3 in Human Acute Leukemias of the Myeloid and Lymphoid Lineages,” Blood: 80(10): 2584-2593 (Nov. 1992). [cited by applicant]
Carow et al., “Expression of the Hematopoietic Growth Factor Receptor FL T3 (STK-1/Flk2) in Human Leukemias,” Blood: 87(3): 1089-1096 (Feb. 1996). [cited by applicant]
Communication pursuant to Rules 161(1) and 162 EPC for European Patent Application 18734624.2, dated Jan. 16, 2020. 3 pages. [cited by applicant]
Human Translation of KR Office Action for KR Application No. 2022-7002509, 6 pgs. [cited by applicant]
JP Office Action for JP Application No. 2019-565897, Jun. 1, 2022, 3 pgs. [cited by applicant]
KR Office Action for KR Application No. 2022-7002509, dated Apr. 1, 2022, 7 pgs. [cited by applicant]
Translation of JP Office Action for JP Application No. 2019-565897, 3 pgs. [cited by applicant]
De Genst et al., “Antibody repertoire development in camelids,” Dev Comp Immunol 2006; 30: 187-98 (Year: 2006). [cited by applicant]
Diamond et al., “Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity”, Proc. Natl. Acad. Sci. USA, 1984, vol. 81, p. 5841-5844. [cited by applicant]
Durben et al., “Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia,” Molecular Therapy, vol. 23, p. 648-655 (2015). [cited by applicant]
Hofmann et al., “Generation, Selection and Preclinical Characterization of an Fe-Optimized FLT3 Antibody for the Treatment of Myeloid Leukemia”, Leukemia, XP055041249, 26(6): 1228-1237, Published Online Jan. 6, 2012. [cited by applicant]
International Search Report for International Appln. No. PCT/IB2018/053908 completed Sep. 3, 2018. 8 pages. [cited by applicant]
Ohno et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH”, Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 2945-2949, abstract. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Nat. Acad. Sci. USA. Immunology. (1982) 79: p. 1979-1983, abstract. [cited by applicant]
Written Opinion of the International Searching Authority for International Appln. No. PCT/IB2018/053908 completed Sep. 3, 2018. 10 pages. [cited by applicant]
Yamamoto et al., “Activating Mutation of D835 within the Activation Loop of FL T3 in Human Hematologic Malignancies,” Blood: 97(8): 2434-2439 (Apr. 2001). [cited by applicant]
Yoshinaga et al., “lg L-chain Shuffling for Affinity Maturation of Phage Library-derived Human Anti-human MCP-1 Antibody Blocking its Chemotactic Activity,” J. Biochem 2008; 143:593-601 (Year: 2008). [cited by applicant]
Fontanelli et al., “Sorafenib as Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia” Clinical Lymphoma Myeloma and Le… [cited by applicant]
Kadia et al., “New drugs in acute myeloid leukemia”, Annals of Oncology, vol. 27, No. 5, pp. 770-778 (9 pages) May 2016. [cited by applicant]
Li et al., “FLT3 Antibody-Based Therapeutics for Leukemia Therapy” International Journal of Hematology, vol. 82, No. 2, 2005, pp. 108-114 (7 pages). [cited by applicant]
Li et al. “Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody”, Blood, vol. 104, No. 4, Aug. 15, 2004, pp. 1137-1144 (8 pages). [cited by applicant]
Piloto et al., “IMC-EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces Nonobese Diabetic/Severe Combined Immunodeficient Engraftment of Some Acute Lymphoblastic Leukemia Cell Lines and Primary Leukemi… [cited by applicant]
Sherbenou et al., “The development of potential antibody-based therapies for myeloma”, Blood Reviews, vol. 29, No. 2, Mar. 2015, pp. 81-91. [cited by applicant]
Small et al., “Targeting FLT3 for the Treatment of Leukemia”, Seminars in Hematology, vol. 45, No. 2, Jul. 2008, pp. S17-S21, DOI: 10.1053/j.seminhematol.2008.07.007 (5 pages). [cited by applicant]
Yamamoto et al., “Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling”, Cancer Science, vol. 103, No. 2, Feb. 2012, pp. 350-359, DOI: 10.1111/j.1349-7006.2011.02141.x (10 pages). [cited by applicant]
Youssoufian et al., “Targeting FMS-Related Tyrosine Kinase Receptor 3 With the Human Immunoglobulin G1 Monoclonal Antibody IMC-EB10”, Cancer, vol. 116, No. 4 Supp, Feb. 15, 2010, pp. 1013-1017 (5 pages). [cited by applicant]
Chen et al. (May 12, 2017) “Targeting FLT3by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia”, Leukemia, 31:1830-1834. [cited by applicant]
Chien et al. (Dec. 2, 2016) “Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia”, Blood, 128(22):1072. [cited by applicant]
Philip et al. (Aug. 21, 2014) “A Highly Compact Epitope-Based Marker/Suicide Gene for Easier and Safer T-cell Therapy”, Blood, 124(8):1277-1287. [cited by applicant]